| Literature DB >> 24743892 |
Yu-Wei Hsieh1, Keh-Chung Lin2, Mallikarjuna Korivi3, Tsong-Hai Lee4, Ching-Yi Wu5, Kuen-Yuh Wu6.
Abstract
We evaluated the reliability of 8-hydroxy-2'-deoxyguanosine (8-OHdG), and determined its ability to predict functional outcomes in stroke survivors. The rehabilitation effect on 8-OHdG and functional outcomes were also assessed. Sixty-one stroke patients received a 4-week rehabilitation. Urinary 8-OHdG levels were determined by liquid chromatography-tandem mass spectrometry. The test-retest reliability of 8-OHdG was good (interclass correlation coefficient=0.76). Upper-limb motor function and muscle power determined by the Fugl-Meyer Assessment (FMA) and Medical Research Council (MRC) scales before rehabilitation showed significant negative correlation with 8-OHdG (r=-0.38, r=-0.30; p<0.05). After rehabilitation, we found a fair and significant correlation between 8-OHdG and FMA (r=-0.34) and 8-OHdG and pain (r=0.26, p<0.05). Baseline 8-OHdG was significantly correlated with post-treatment FMA, MRC, and pain scores (r=-0.34, -0.31, and 0.25; p<0.05), indicating its ability to predict functional outcomes. 8-OHdG levels were significantly decreased, and functional outcomes were improved after rehabilitation. The exploratory study findings conclude that 8-OHdG is a reliable and promising biomarker of oxidative stress and could be a valid predictor of functional outcomes in patients. Monitoring of behavioral indicators along with biomarkers may have crucial benefits in translational stroke research.Entities:
Mesh:
Substances:
Year: 2014 PMID: 24743892 PMCID: PMC4013643 DOI: 10.3390/ijms15046504
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Demographic and clinical characteristics of the patients with stroke (N = 61).
| Characteristics | Value |
|---|---|
|
| |
| Mean ± SD or No. (%) | |
| Age, years | 54.60 ± 10.96 |
|
| |
| Time after stroke, months | 23.46 ± 14.00 |
|
| |
| Sex | |
|
| |
| Male | 39 (63.9) |
| Female | 22 (36.1) |
|
| |
| Side of stroke | |
|
| |
| Right | 35 (57.4) |
| Left | 26 (42.6) |
|
| |
| Stroke type | |
|
| |
| Ischemic | 37 (60.7) |
| Hemorrhagic | 24 (39.3) |
|
| |
| Smoker | 3 (4.9) |
|
| |
| Drinker | 4 (6.6) |
|
| |
| Antioxidants intake | 26 (42.6) |
|
| |
| Comorbidities | |
|
| |
| Hypertension | 41 |
| Diabetes mellitus | 23 |
| Heat disease | 18 |
| Osteoarthritis | 5 |
| Hyperlipidemia | 2 |
| Gout | 1 |
| Epilepsy | 1 |
| Thalassemia | 1 |
The test-retest reliability of 8-OHdG from the two baseline measures in patients with stroke (N = 45). Abbreviations: 8-OHdG, 8-hydroxy-2′-deoxyguanosine; CI, confidence interval; ICC, intraclass correlation coefficient; SD, standard deviation.
| Variable | 8-OHdG (ng/mg creatinine) (Mean ± SD) | Mean difference | ICC (95% CI) |
|---|---|---|---|
| Baseline 1 | 5.87 ± 2.77 | ||
| Baseline 2 | 5.60 ± 2.47 | 0.27 | 0.76 (0.60–0.86) |
Figure 1.The Bland-Altman plot shows the test-retest reliability of urinary 8-hydroxy-2′-deoxyguanosine (8-OHdG) levels. The reference lines show the mean differences between baseline 1 and baseline 2 assessments of 8-OHdG (solid line: 0.27), and the 95% limits of agreement for the mean difference (dotted lines: −3.30 and 3.84).
Correlations between 8-OHdG levels and functional outcomes before and after rehabilitation intervention (N = 61). Abbreviations: 8-OHdG, 8-hydroxy-2′-deoxyguanosine; CI, confidence interval; FMA, Fugl-Meyer Assessment; and MRC, Medical Research Council scale.
| Functional outcome | Pearson | |
|---|---|---|
|
| ||
| Pre-treatment | Post-treatment | |
| FMA | −0.38 | −0.34 |
| MRC | −0.30 | −0.19 (−0.42 to 0.06) |
| Fatigue | 0.21 (−0.04 to 0.44) | 0.18 (−0.08 to 0.41) |
| Pain | 0.13 (−0.13 to 0.37) | 0.26 |
p < 0.05.
Predictive ability of pre-treatment 8-OHdG levels on post-treatment functional outcomes in stroke patients (N = 61). Abbreviations: 8-OHdG, 8-hydroxy-2′-deoxyguanosine; CI, confidence interval; FMA, Fugl-Meyer Assessment; and MRC, Medical Research Council scale.
| Functional outcome | Pearson |
|---|---|
| FMA | −0.34 |
| MRC | −0.31 |
| Fatigue | 0.21 (−0.04 to 0.44) |
| Pain | 0.25 |
p < 0.05.
Effects of 4-week rehabilitation intervention on 8-OHdG levels and functional outcomes in patients with stroke (N = 61). Abbreviations: 8-OHdG, 8-hydroxy-2′-deoxyguanosine; FMA, Fugl-Meyer Assessment; MRC, Medical Research Council scale; SD, standard deviation.
| Measurement (units) | Pre-treatment (Mean ± SD) | Post-treatment (Mean ± SD) | |
|---|---|---|---|
| 8-OHdG (ng/mg creatinine) | 5.02 ± 2.72 | 4.46 ± 2.37 | 0.04 |
| FMA (0–66) | 43.75 ± 8.96 | 47.70 ± 9.13 | <0.01 |
| MRC (0–5) | 3.57 ± 0.64 | 3.79 ± 0.64 | <0.01 |
| Fatigue (0–10) | 2.32 ± 2.47 | 2.16 ± 2.34 | 0.53 |
| Pain (0–10) | 1.82 ± 2.56 | 1.08 ± 1.83 | 0.02 |
p < 0.05.